[go: up one dir, main page]

MA31763B1 - Inhibiteurs de kinase de type polo - Google Patents

Inhibiteurs de kinase de type polo

Info

Publication number
MA31763B1
MA31763B1 MA32753A MA32753A MA31763B1 MA 31763 B1 MA31763 B1 MA 31763B1 MA 32753 A MA32753 A MA 32753A MA 32753 A MA32753 A MA 32753A MA 31763 B1 MA31763 B1 MA 31763B1
Authority
MA
Morocco
Prior art keywords
kinase inhibitors
compounds
inhibitors type
polo
type polo
Prior art date
Application number
MA32753A
Other languages
Arabic (ar)
English (en)
Inventor
Sheldon X Cao
Victoria Feher
Takashi Ichikawa
Benjamin Jones
Stephen W Kaldor
Andre A Kiryanov
Yan Liu
Christopher Mcbride
Srinivasa Reddy Natala
Zhe Nie
Jeffrey A Stafford
Betty Lam
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40219644&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31763(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA31763B1 publication Critical patent/MA31763B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

Abstract

La présente invention concerne des composés répondant à la formule suivante, lesquels sont destinés à être utilisés avec des kinases : (i), les variables étant telles que définies dans le présent document. L'invention concerne également des compositions pharmaceutiques, des trousses et des articles de fabrication contenant de tels composés, des procédés et des intermédiaires utiles pour la fabrication des composés, et des procédés d'utilisation desdits composés
MA32753A 2007-09-25 2010-04-08 Inhibiteurs de kinase de type polo MA31763B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97512707P 2007-09-25 2007-09-25
US3730308P 2008-03-17 2008-03-17
PCT/US2008/077558 WO2009042711A1 (fr) 2007-09-25 2008-09-24 Inhibiteurs de kinase de type polo

Publications (1)

Publication Number Publication Date
MA31763B1 true MA31763B1 (fr) 2010-10-01

Family

ID=40219644

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32753A MA31763B1 (fr) 2007-09-25 2010-04-08 Inhibiteurs de kinase de type polo

Country Status (26)

Country Link
US (4) US20110201818A1 (fr)
EP (3) EP2564850B1 (fr)
JP (2) JP5372939B2 (fr)
KR (2) KR101444924B1 (fr)
CN (2) CN101917995A (fr)
AR (1) AR071729A1 (fr)
AU (1) AU2008304417B2 (fr)
BR (1) BRPI0817315A2 (fr)
CA (2) CA2699607A1 (fr)
CL (1) CL2008002852A1 (fr)
CO (1) CO6270231A2 (fr)
CR (1) CR11370A (fr)
DO (1) DOP2010000091A (fr)
EA (1) EA019487B1 (fr)
EC (1) ECSP10010129A (fr)
ES (1) ES2488966T3 (fr)
GE (1) GEP20125704B (fr)
MA (1) MA31763B1 (fr)
MX (2) MX2010003249A (fr)
MY (1) MY152283A (fr)
NZ (1) NZ584760A (fr)
PE (1) PE20090710A1 (fr)
TN (1) TN2010000131A1 (fr)
TW (1) TWI436769B (fr)
WO (2) WO2009042711A1 (fr)
ZA (1) ZA201002543B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE479434T1 (de) 2006-02-14 2010-09-15 Vertex Pharma Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine
EA019487B1 (ru) 2007-09-25 2014-04-30 Такеда Фармасьютикал Компани Лимитед Соединения в качестве ингибиторов plk, фармацевтические композиции, их содержащие, и их применение
EP2610256B1 (fr) * 2007-09-28 2016-04-27 Cyclacel Limited Dérivés de pyrimidine en tant qu'inhibiteurs de kinase de protéine
JP2011527667A (ja) 2008-06-18 2011-11-04 武田薬品工業株式会社 ハロ置換ピリミドジアゼピン
US8049005B2 (en) 2009-03-31 2011-11-01 Arqule, Inc. Substituted tetrahydropyrazolo-pyrido-azepine compounds
WO2010115279A1 (fr) 2009-04-06 2010-10-14 University Health Network Inhibiteurs de kinases et procédé de traitement du cancer avec ceux-ci
JP2013505927A (ja) 2009-09-25 2013-02-21 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼ阻害剤として有用なピリミジン誘導体の調製方法
KR20120096474A (ko) 2009-09-25 2012-08-30 버텍스 파마슈티칼스 인코포레이티드 단백질 키나제 억제제로서 유용한 피리미딘 유도체의 제조 방법
KR20120120252A (ko) 2009-12-23 2012-11-01 엘란 파마슈티칼스, 인크. 폴로-유사 키나제의 억제제로서의 프테리디논
JP5442906B2 (ja) 2010-04-06 2014-03-19 ユニバーシティ・ヘルス・ネットワーク キナーゼインヒビターおよびこれを用いた癌の治療方法
WO2012061342A2 (fr) 2010-11-01 2012-05-10 Arqule, Inc. Composés de benzo-imidazo-pyrido-diazépine substitués
WO2013005425A1 (fr) * 2011-07-07 2013-01-10 イハラケミカル工業株式会社 Procédé de fabrication d'un composé nitrobenzène
WO2013058344A1 (fr) * 2011-10-21 2013-04-25 武田薬品工業株式会社 Procédé de prédiction de l'effet d'un inhibiteur de plk1
TWI659952B (zh) 2013-10-18 2019-05-21 健康網路大學 Ｐｌｋ－４抑制劑之鹽和結晶形式
US10793571B2 (en) 2014-01-31 2020-10-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
CN106029653A (zh) 2014-01-31 2016-10-12 达纳-法伯癌症研究所股份有限公司 二氨基嘧啶苯砜衍生物及其用途
MX2017001756A (es) 2014-08-08 2017-05-30 Dana Farber Cancer Inst Inc Derivados de diazepano y sus usos.
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
HK1256417A1 (zh) 2015-09-11 2019-09-20 达纳-法伯癌症研究所股份有限公司 氰基噻吩並三唑並二氮雜環庚三烯及其用途
CR20180199A (es) 2015-09-11 2018-05-25 Dana Farber Cancer Inst Inc Acetamida tienotriazolodiazepinas y usos de las mismas
RU2742035C2 (ru) 2015-11-25 2021-02-01 Дана-Фарбер Кэнсер Инститьют, Инк. Бивалентные ингибиторы бромодоменов и пути их применения
TW202506629A (zh) * 2016-05-05 2025-02-16 美商嘉來克生命科學有限責任公司 整合應激途徑之調節劑
KR20220004102A (ko) 2019-04-24 2022-01-11 유니버시티 헬스 네트워크 Plk4 억제제 (1r,2s)-(e)-2-(3-(4-((시스-2,6-디메틸모르폴리노)메틸)스티릴)-1h-이미다졸-6-일)-5'-메톡시스피로[시클로프로판-1,3'-인돌린]-2'-온 푸마레이트의 결정 형태 s4
WO2021194318A1 (fr) 2020-03-27 2021-09-30 Uppthera Composé induisant une dégradation sélective de plk1
WO2022145989A1 (fr) * 2020-12-31 2022-07-07 (주) 업테라 Dérivé de pyrimidodiazépine servant d'inhibiteur sélectif de plk1
EP4289852A4 (fr) * 2021-02-08 2025-02-26 NovaOnco JS Therapeutics Co., Ltd. Composé de 5,6-dihydrothiéno[3,4-h]quinazoline
WO2024229406A1 (fr) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Polythérapie pour une maladie ou un trouble lié à ras
WO2025034702A1 (fr) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 destiné à être utilisé dans le traitement d'une maladie ou d'un trouble lié à une protéine ras
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (fr) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025240847A1 (fr) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025255438A1 (fr) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Procédés de traitement d'une maladie ou d'un trouble lié à la protéine ras

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
SK3542002A3 (en) 1999-09-15 2003-04-01 Warner Lambert Co Pteridinones as kinase inhibitors
CN1390220A (zh) 1999-09-17 2003-01-08 艾博特股份有限两合公司 作为治疗剂的激酶抑制剂
HRP20040213A2 (en) 2001-09-04 2005-02-28 Boehringer Ingelheim Pharma Gmbh & Co.Kg Novel dihydropteridinones, method for producing the same and the use thereof as medicaments
US6806272B2 (en) 2001-09-04 2004-10-19 Boehringer Ingelheim Pharma Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
EP1630163A1 (fr) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinones, procédés de préparation et leur utilisation en tant que médicaments
EP1632493A1 (fr) 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dérivés de dihydropteridine, méthodes de préparation et utilisation en tant que médicament
WO2006021548A1 (fr) 2004-08-27 2006-03-02 Boehringer Ingelheim International Gmbh Dihydropteridinones, leur procede de production, et leur utilisation en tant que medicaments
ATE479434T1 (de) 2006-02-14 2010-09-15 Vertex Pharma Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine
EP2029599A1 (fr) 2006-05-19 2009-03-04 Astra Zeneca AB Composés de dihydroptéridine en tant qu'agents antiprolifératifs
TW200808325A (en) * 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
KR101157848B1 (ko) * 2007-03-22 2012-07-11 다케다 야쿠힌 고교 가부시키가이샤 Ｐｌｋ１ 저해제로서 유용한 치환된 피리미도디아제핀
CA2695753A1 (fr) 2007-08-15 2009-02-19 Vertex Pharmaceuticals Incorporated Composes utilises comme inhibiteurs de proteines kinases
EA019487B1 (ru) * 2007-09-25 2014-04-30 Такеда Фармасьютикал Компани Лимитед Соединения в качестве ингибиторов plk, фармацевтические композиции, их содержащие, и их применение
EP2610256B1 (fr) 2007-09-28 2016-04-27 Cyclacel Limited Dérivés de pyrimidine en tant qu'inhibiteurs de kinase de protéine
JP2011527667A (ja) * 2008-06-18 2011-11-04 武田薬品工業株式会社 ハロ置換ピリミドジアゼピン

Also Published As

Publication number Publication date
EP2197442B1 (fr) 2012-09-12
US20090281092A1 (en) 2009-11-12
BRPI0817315A2 (pt) 2015-03-17
AU2008304417B2 (en) 2013-07-18
EA019487B1 (ru) 2014-04-30
AU2008304417A1 (en) 2009-04-02
ES2488966T3 (es) 2014-09-01
CN103122001A (zh) 2013-05-29
CR11370A (es) 2010-07-16
WO2009042711A1 (fr) 2009-04-02
JP5372939B2 (ja) 2013-12-18
TW200927135A (en) 2009-07-01
US8318727B2 (en) 2012-11-27
CA2699607A1 (fr) 2009-04-02
KR20140097440A (ko) 2014-08-06
MX2010003244A (es) 2010-04-21
AR071729A1 (es) 2010-07-14
MX2010003249A (es) 2010-11-09
EA201070395A1 (ru) 2010-10-29
KR101444924B1 (ko) 2014-10-07
US20110082111A1 (en) 2011-04-07
MY152283A (en) 2014-09-15
EP2205241A1 (fr) 2010-07-14
DOP2010000091A (es) 2010-07-31
EP2205241B1 (fr) 2014-05-21
WO2009042806A1 (fr) 2009-04-02
HK1145144A1 (en) 2011-04-08
CA2700295A1 (fr) 2009-04-02
TN2010000131A1 (en) 2011-09-26
CN101917995A (zh) 2010-12-15
KR20100087292A (ko) 2010-08-04
NZ584760A (en) 2012-03-30
ZA201002543B (en) 2011-11-30
WO2009042711A4 (fr) 2009-06-04
US20100222575A1 (en) 2010-09-02
ECSP10010129A (es) 2010-06-29
GEP20125704B (en) 2012-12-10
EP2197442A1 (fr) 2010-06-23
EP2564850B1 (fr) 2014-08-13
JP2010540463A (ja) 2010-12-24
PE20090710A1 (es) 2009-07-15
JP2010540464A (ja) 2010-12-24
US8202990B2 (en) 2012-06-19
US8026234B2 (en) 2011-09-27
EP2564850A1 (fr) 2013-03-06
TWI436769B (zh) 2014-05-11
US20110201818A1 (en) 2011-08-18
CO6270231A2 (es) 2011-04-20
CL2008002852A1 (es) 2009-03-27

Similar Documents

Publication Publication Date Title
MA31763B1 (fr) Inhibiteurs de kinase de type polo
MA32615B1 (fr) Inhibiteurs de cmet
MA31151B1 (fr) Inhibiteurs de mapk/erk kinase
MA32391B1 (fr) Activateurs de la glucokinase
MA32104B1 (fr) Dérivés d'oxime en tant qu'inhibiteurs de hsp90
MA30057B1 (fr) Nucleosides antiviraux
TNSN08196A1 (fr) Derives de pyrazine
MA31586B1 (fr) Dérivés d'alcools alkyliques de 1-phényl-2-pyridinyle en tant qu'inhibiteurs de la phosphodiestérase
MA29160B1 (fr) Derives de triazole substitues, servant d'antagonistes d'ocytocine
MA30784B1 (fr) Derives phenyliques et utilisation de ceux-ci en tant qu'immunomodulateurs.
TNSN08359A1 (fr) Derives d'amines
MA29629B1 (fr) Inhibiteurs de l'histone deacetylase
MA31683B1 (fr) Composes et procedes pour moduler fxr
MA31580B1 (fr) Derives de bicyclolactames substitués
ATE479687T1 (de) Kinaseinhibitoren
TW200608977A (en) Substituted 2-alkyl quinazolinone derivatives as parp inhibitors
MA31419B1 (fr) Derives de pyridine
MA30781B1 (fr) Inhibiteur de kinase
UA88012C2 (uk) Похідні хіназоліндіону як інгібітори parp
MA29393B1 (fr) Derives d'azole sous forme d'inhibiteurs de lipase et de phospholipase
DK2134691T3 (da) Quinolinonderivativer som parp- og tank-inhibitorer
MA31655B1 (fr) Pyrimidines cyclopenta [d] hydroxylés et méthoxylés utilisés en tant qu'inhibiteurs de la protéine kinase akt.
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
TNSN07305A1 (fr) Agonistes de pyy et leurs utilisations
TW200745045A (en) Imidazole based LXR modulators